SLC5A2 and atrial fibrillation: After excluding 8381 patients from the non‐SGLT2 inhibitor group and 8846 patients from the SGLT2 inhibitor group due to history of AF prior to the observation period (Table 2), SGLT2 inhibitor use was associated with a 19% lower risk of incident AF (HR 0.81 [95% CI 0.76‐0.84]; log rank P value <0.0001) and longer AF‐free survival.